Amgen tumbles to year's low despite weightloss trial success
Portfolio Pulse from
Amgen Inc's shares fell 11.6% to a year's low despite successful results from a Phase II trial of its weight-loss drug, MariTide, which showed significant weight loss in participants.
November 26, 2024 | 4:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Amgen's stock fell 11.6% to a year's low despite positive results from a Phase II trial of its weight-loss drug, MariTide, which showed significant weight loss in participants.
Despite the positive trial results for MariTide, Amgen's stock fell significantly. This suggests that investors may have had higher expectations or concerns about other aspects of the company's performance or market conditions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100